Sharda Cropchem Strong Q3 & 9M FY26 Results Driven by Volume and Product Mix

Sharda Cropchem announced robust financial results for Q3 and the nine months of FY26. Revenue for Q3 FY26 reached ₹1,288.8 crores, a 39% increase Y-o-Y. The company achieved its highest-ever annual PAT in 9M FY26 and declared an interim dividend of ₹6 per equity share. Growth was primarily driven by volume and product mix improvements.

Financial Performance Highlights

Sharda Cropchem reported a strong performance for the third quarter and nine months ended December 31, 2025. Key highlights include:

  • Revenue for Q3 FY26: ₹1,288.8 crores, up 39% Y-o-Y
  • Gross Profit for Q3 FY26: ₹450.3 crores, up 48% Y-o-Y
  • EBITDA for Q3 FY26: ₹245.5 crores, up 59% Y-o-Y
  • PAT for Q3 FY26: ₹145.1 crores, a significant increase of 366% Y-o-Y
  • Revenue for 9M FY26: ₹3,202.7 crores, up 29% Y-o-Y
  • Gross Profit for 9M FY26: ₹1,120.2 crores, up 50% Y-o-Y
  • EBITDA for 9M FY26: ₹526.7 crores, up 64% Y-o-Y
  • PAT for 9M FY26: ₹362.3 crores, a substantial increase of 259% Y-o-Y
  • EPS for 9M FY26 reached ₹40.15.

The company has announced an interim dividend of ₹6 per equity share.

Segment-Wise Revenue Breakup

The Agrochemical segment contributed significantly to the revenue:

  • Agrochemical Segment (Q3 FY26): ₹1,141 crores, up 48% Y-o-Y
  • Non-Agro Segment (Q3 FY26): ₹148 crores, down 8% Y-o-Y

Product-Wise Revenue Breakup

Key product categories performed strongly:

  • Herbicides (Q3 FY26): ₹663 crores, up 43% Y-o-Y
  • Insecticides (Q3 FY26): ₹218 crores, up 43% Y-o-Y
  • Fungicides (Q3 FY26): ₹260 crores, up 71% Y-o-Y

Regional Performance

Europe showed particularly strong growth:

  • Europe (Q3 FY26): ₹654 crores, up 123% Y-o-Y

Key Business Highlights

  • Agrochemical segment contributed 89% to Q3 FY26 revenues.
  • Overall volumes increased by 14.4% Y-o-Y in Q3 FY26.
  • Product Registrations stand at 3,004 with 1,076 applications pending as of December 31, 2025.
  • The company remains debt-free with cash, bank, and liquid investments of ₹826 crores.

Management Commentary

Mr. Ramprakash Bubna, Chairman and MD, commented, “In Q3 FY26, we delivered robust revenue growth of 39% YoY to ₹1,289 crores, mainly driven by a mix of volume and product mix. Europe has led as the key contributor in both volume and value terms…The Company has already achieved its highest-ever annual PAT within the first nine months of FY26 of ₹362 crores.”

Source: BSE

Previous Article

TARC Limited Board Meeting Scheduled to Approve Financial Results

Next Article

Aarti Pharmalabs Board Meeting Scheduled to Approve Quarterly Results